SARS-CoV-2 (COVID-19) Envelope Antibody (biotin)
Code | Size | Price |
---|
PSI-3531-biotin-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-3531-biotin-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Virus
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
blue ice or RT
Storage:
SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody can be stored at 4 ˚ C for three months and -20 ˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Images
Documents
Further Information
Additional Names:
SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope Antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Envelope protein, E protein
Application Note:
IHC: 2 μg/mL
Antibody validated: Immunohistochemistry in COVID-19 patient samples. All other applications and species not yet tested.
Antibody validated: Immunohistochemistry in COVID-19 patient samples. All other applications and species not yet tested.
Background:
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019?20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3).
Background References:
- Gorbalenya. bioRxiv: 2020.
- Hui et al. Int J Infect Dis. 2020;91:264-266.
- Pervushin et al. PLoS Pathog. 2009; 5(7): e1000511.
Buffer:
SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Biotin
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted reactivity based on immunogen sequence: SARS-CoV Envelope proteins: (100%)
Immunogen:
Anti-SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody (3531) was raised against a peptide corresponding to 10 amino acids near the amino terminus of SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope protein.
The immunogen is located within the first 50 amino acids of SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope.
The immunogen is located within the first 50 amino acids of SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope.
ISOFORMS:
SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope has one isoform (75aa).
NCBI Gene ID #:
43740570
NCBI Official Name:
envelope protein
NCBI Official Symbol:
E
NCBI Organism:
Wuhan seafood market pneumonia virus
Physical State:
Liquid
Protein Accession #:
QHD43418
Protein GI Number:
1791269092
Purification:
SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope Antibody is affinity chromatography purified via peptide column.
Research Area:
Infectious Disease,COVID-19
Swissprot #:
QHD43418
User NOte:
Optimal dilutions for each application to be determined by the researcher.
References
- Nuovo GJ et al. Cytologic and molecular correlates of?SARS-CoV-2 infection of the nasopharynx. Ann Diagn Pathol. 2020; 48:151565. doi: 10.1016/j.anndiagpath.2020.151565. PMID: 32659620
- Magro C, Mulvey JJ, Laurence J, Sanders S, Crowson N, Grossman M, Harp J, Nuovo G. The differing pathophysiologies that underlie COVID-19 associated perniosis and thrombotic retiform purpura: a case series. Br J Dermatol. 2020; 22:10.1111/bjd.19415. doi: 10.1111/bjd.19415. PMID: 32779733
- Nuovo G, Tili E, Suster D, Matys E, Hupp L, Magro C. Strong homology between SARS-CoV-2 envelope protein and a Mycobacterium sp. antigen allows rapid diagnosis of Mycobacterial infections and may provide specific anti-SARS-CoV-2 immunity via the BCG vaccine. Ann Diagn Pathol. 2020; 48:151600. doi: 10.1016/j.anndiagpath.2020.151600. PMID: 32805515
- Ko, et al. Discordant anti-SARS-CoV-2 spike protein and RNA staining in cutaneous perniotic lesions suggests endothelial deposition of cleaved spike protein. J Cutan Pathol . 2021 Jan;48(1):47-52. doi: 10.1111/cup.13866. Epub 2020 Oct 1.PMID: 32895985?
- Magro, et al. Docked severe acute respiratory syndrome coronavirus 2 proteins within the cutaneous and subcutaneous microvasculature and their role in the pathogenesis of severe coronavirus disease 2019. Hum Pathol. 2020 Dec;106:106-116. doi: 10.1016/j.humpath.2020.10.002. Epub 2020 Oct 12.PMID: 33058948
- Magro, et al. The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series. Br J Dermatol. 2020 Jul 22;10.1111/bjd.19415. doi: 10.1111/bjd.19415PMID: 32779733
- Mulvey, et al. Analysis of complement deposition and viral RNA in placentas of COVID-19 patients. Ann Diagn Pathol. 2020 Jun;46:151530. doi: 10.1016/j.anndiagpath.2020.151530. Epub 2020 Apr 25.PMID: 32387855
- Rotman, et al. Concomitant calciphylaxis and COVID-19 associated thrombotic retiform purpura. Skeletal Radiol. 2020 Nov;49(11):1879-1884. doi: 10.1007/s00256-020-03579-6. Epub 2020 Aug 26.PMID: 32844243